Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
290.64B
Market cap290.64B
Price-Earnings ratio
16.16
Price-Earnings ratio16.16
Dividend yield
2.79%
Dividend yield2.79%
Average volume
17.10M
Average volume17.10M
High today
$118.16
High today$118.16
Low today
$116.10
Low today$116.10
Open price
$117.80
Open price$117.80
Volume
11.85M
Volume11.85M
52 Week high
$122.66
52 Week high$122.66
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

With a market cap of 290.64B, Merck(MRK) trades at $116.70. The stock has a price-to-earnings ratio of 16.16 and currently yields dividends of 2.8%.

As of 2026-02-11, Merck(MRK) stock has fluctuated between $116.10 and $118.16. The current price stands at $116.70, placing the stock +0.5% above today's low and -1.2% off the high.

The Merck(MRK)'s current trading volume is 11.85M, compared to an average daily volume of 17.1M.

In the last year, Merck(MRK) shares hit a 52-week high of $122.66 and a 52-week low of $73.31.

In the last year, Merck(MRK) shares hit a 52-week high of $122.66 and a 52-week low of $73.31.

MRK News

TipRanks 5h
Top Merck Executive Makes Major Move With Multi-Million-Dollar Stock Sale

New insider activity at Merck & Company ( (MRK) ) has taken place on February 10, 2026. Executive VP & President, MRL, Dean Y. Li has executed a notable inside...

TipRanks 10h
FDA approves Merck’s Keytruda, Keytruda Qlex for platinum-resistant carcinomas

The Food and Drug Administration approved pembrolizumab, Keytruda from Merck (MRK), as well as pembrolizumab and berahyaluronidase alfa-pmph or Keytruda Qlex fr...

Simply Wall St 11h
Merck Broadens Growth Drivers With Women’s Health And Infant RSV Moves

Merck (NYSE:MRK) has entered a collaboration with Calla Lily Clinical Care to develop a novel intravaginal drug delivery platform using the Callavid device. He...

Merck Broadens Growth Drivers With Women’s Health And Infant RSV Moves

Analyst ratings

57%

of 28 ratings
Buy
57.1%
Hold
42.9%
Sell
0%

More MRK News

The Motley Fool 1d
Should You Buy Moderna Before Feb. 13?

The biotech has momentum as its quarterly report approaches. Moderna (MRNA +2.24%) has been on fire this year, with the biotech's shares up by 39% through Feb....

Should You Buy Moderna Before Feb. 13?
Simply Wall St 2d
Why Merck Is Up 7.6% After RSV Win ENFLONSIA And Steady 2026 Guidance

In early February 2026, Merck reported full-year 2025 sales of US$65.01 billion and earnings per share of US$7.28, issued 2026 sales guidance of US$65.5–67.0 bi...

Why Merck Is Up 7.6% After RSV Win ENFLONSIA And Steady 2026 Guidance
Simply Wall St 3d
Assessing Merck Valuation After Enflonsia Approval And Steady Keytruda Momentum

Advertisement Why Health Canada’s Enflonsia approval matters for Merck (MRK) Merck (MRK) just picked up Health Canada approval for Enflonsia, an RSV monoclona...

Assessing Merck Valuation After Enflonsia Approval And Steady Keytruda Momentum
Simply Wall St 4d
Health Canada RSV Decision Adds New Piece To Merck Growth Story

Health Canada has approved Merck's ENFLONSIA (clesrovimab), a monoclonal antibody for the prevention of respiratory syncytial virus (RSV) in newborns and infant...

Health Canada RSV Decision Adds New Piece To Merck Growth Story
TipRanks 4d
Wave of Insider Moves as Merck’s Top Brass Cash In on Company Stock

New insider activity at Merck & Company ( (MRK) ) has taken place on February 6, 2026. Multiple top executives at Merck & Company have recently executed sizabl...

Simply Wall St 5d
Merck Rebuilds Beyond Keytruda With Pipeline Deals And Ebola Vaccine Bet

Merck reported significant pipeline progress and new product launches as it prepares for the eventual loss of Keytruda exclusivity. The company expanded its po...

Merck Rebuilds Beyond Keytruda With Pipeline Deals And Ebola Vaccine Bet
TipRanks 7d
Merck price target raised to $133 from $120 at Goldman Sachs

Goldman Sachs analyst Asad Haider raised the firm’s price target on Merck (MRK) to $133 from $120 and keeps a Buy rating on the shares. Merck shares rose 2.2% d...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.